Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

Abstract

Neuroendocrine carcinomas (NEC) are tumors expressing markers of neuronal differentiation that can arise at different anatomic sites but have strong histological and clinical similarities. Here we report the chromatin landscapes of a range of human NECs and show convergence to the activation of a common epigenetic program. With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xenograft (PDX) models and human clinical samples to show the existence of two distinct NEPC subtypes based on the expression of the neuronal transcription factors ASCL1 and NEUROD1. While in cell lines and PDX models these subtypes are mutually exclusive, single-cell analysis of human clinical samples exhibits a more complex tumor structure with subtypes coexisting as separate sub-populations within the same tumor. These tumor sub-populations differ genetically and epigenetically contributing to intra- and inter-tumoral heterogeneity in human metastases. Overall, our results provide a deeper understanding of the shared clinicopathological characteristics shown by NECs. Furthermore, the intratumoral heterogeneity of human NEPCs suggests the requirement of simultaneous targeting of coexisting tumor populations as a therapeutic strategy.

References 67

1. 1.
   Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas · 2017

   Not checked
2. 2.

   Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.

   Not in our library10.1097/mpa.0b013e3181ec124e

3. 3.

   Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 2017;23:1-10.

   Not in our library10.1038/nm.4341

4. 4.

   Cheng J, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathog. 2017;13:e1006668.

   Not in our library10.1371/journal.ppat.1006668

5. 5.

   Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018;36:2492-2503.

   Not in our library10.1200/jco.2017.77.6880

6. 6.

   Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.

   Not in our library10.1016/s1470-2045(14)71180-5

7. 7.

   Rudin CM, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer. 2019;19:289-297.

   Not in our library10.1038/s41568-019-0133-9

8. 8.

   Neptune ER, et al. Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J. Biol. Chem. 2008;283:21160-21169.

   Not in our library10.1074/jbc.m708692200

9. 9.

   Ito T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development. 2000;127:3913-3921.

   Not in our library10.1242/dev.127.18.3913

10. 10.
    ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs · 2016

    Not checked
11. 11.

    Balanis NG, et al. Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies. Cancer Cell. 2019;36:17-34.e7.

    Not in our library10.1016/j.ccell.2019.06.005

12. 12.

    Nguyen HM, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate. 2017;77:654-671.

    Not in our library10.1002/pros.23313

13. 13.

    Drapkin BJ, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Disco. 2018;8:600-615.

    Not in our library10.1158/2159-8290.cd-17-0935

14. 14.

    Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science362, eaav1898 (2018).

    Not in our library10.1126/science.aav1898

15. 15.

    Park JW, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362:91-95.

    Not in our library10.1126/science.aat5749

16. 16.

    Labrecque MP, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 2019;129:4492-4505.

    Not in our library10.1172/jci128212

17. 17.

    McLean CY, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 2010;28:495-501.

    Not in our library10.1038/nbt.1630

18. 18.

    Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell. 2010;38:576-589.

    Not in our library10.1016/j.molcel.2010.05.004

19. 19.

    Fan K, et al. MCPyV large T antigen-induced atonal homolog 1 is a lineage-dependency oncogene in Merkel cell carcinoma. J. Invest. Dermatol. 2020;140:56-65.e3.

    Not in our library10.1016/j.jid.2019.06.135

20. 20.

    Park DE, et al. Author correction: Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat. Cell Biol. 2020;22:752.

    Not in our library10.1038/s41556-020-0533-9

21. 21.

    Augustyn A, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc. Natl. Acad. Sci. USA. 2014;111:14788-14793.

    Not in our library10.1073/pnas.1410419111

22. 22.

    Denny SK, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166:328-342.

    Not in our library10.1016/j.cell.2016.05.052

23. 23.

    Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012;44:1111-1116.

    Not in our library10.1038/ng.2405

24. 24.

    Horie M, et al. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer. J. Pathol. 2018;246:154-165.

    Not in our library10.1002/path.5109

25. 25.

    Zheng R, et al. Cistrome data browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47:D729-D735.

    Not in our library10.1093/nar/gky1094

26. 26.

    Layer RM, et al. GIGGLE: a search engine for large-scale integrated genome analysis. Nat. Methods. 2018;15:123-126.

    Not in our library10.1038/nmeth.4556

27. 27.

    Borges M, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997;386:852-855.

    Not in our library10.1038/386852a0

28. 28.

    Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25-29.

    Not in our library10.1038/75556

29. 29.

    DeLucia DC, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin. Cancer Res. 2021;27:759-774.

    Not in our library10.1158/1078-0432.ccr-20-3396

30. 30.

    Saint-André V, et al. Models of human core transcriptional regulatory circuitries. Genome Res. 2016;26:385-396.

    Not in our library10.1101/gr.197590.115

31. 31.

    Wapinski OL, et al. Rapid chromatin switch in the direct reprogramming of fibroblasts to neurons. Cell Rep. 2017;20:3236-3247.

    Not in our library10.1016/j.celrep.2017.09.011

32. 32.

    Matsushita M, et al. Neural differentiation of human embryonic stem cells induced by the transgene-mediated overexpression of single transcription factors. Biochem. Biophys. Res. Commun. 2017;490:296-301.

    Not in our library10.1016/j.bbrc.2017.06.039

33. 33.

    Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016;22:298-305.

    Not in our library10.1038/nm.4045

34. 34.

    Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 2018;36:411-420.

    Not in our library10.1038/nbt.4096

35. 35.
    CopywriteR: DNA copy number detection from off-target sequence data · 2015

    No notice
36. 36.

    Satpathy AT, et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat. Biotechnol. 2019;37:925-936.

    Not in our library10.1038/s41587-019-0206-z

37. 37.

    Ireland AS, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60-78.e12.

    Not in our library10.1016/j.ccell.2020.05.001

38. 38.

    Culine S, et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007;178:844-848.

    Not in our library10.1016/j.juro.2007.05.044

39. 39.

    Aparicio AM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 2013;19:3621-3630.

    Not in our library10.1158/1078-0432.ccr-12-3791

40. 40.

    Taplin, M. E. et al. A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 37, TPS398-TPS398 (2018).

    Not in our library

Cited by papers we hold 4

• Liquid biopsy epigenomic profiling for cancer subtyping · 2023
  Corrected
• Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models · 2022
  No notice
• ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer · 2022
  No notice
• Complexities of Prostate Cancer · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.